Ignite Creation Date:
2024-10-25 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06532110
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-29
Brief Title:
Gut Microbiota in Chronic GI Diseases
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Role of Gut Microbiota in Chronic GI Diseases A Pilot Study
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ChronicGI
Brief Summary:
The study involves characterizing the microbiota of patients with IBS functional diarrhea IBD severe motility disorders and celiac disease
This will be complemented by a translational phase of human-mouse hybrid experiments in which germ-free mice will be colonized with feces from these patients with different GI disease and non-disease controls and we will compare symptoms microbiota composition and histological changes in the gut and in the brain of the mice
This will be complemented by a translational phase of human-mouse hybrid experiments in which germ-free mice will be colonized with feces from these patients with different GI disease and non-disease controls and we will compare symptoms microbiota composition and histological changes in the gut and in the brain of the mice
Detailed Description:
A complex community of microbes collectively referred to as microbiota inhabit the human body The intestinal microbiota is a diverse and dynamic ecosystem which has developed a mutualistic relationship with its host and plays a crucial role in the development of the hosts innate and adaptive immune responses This ecosystem serves the host by protecting against pathogens harvesting otherwise inaccessible nutrients aiding in neutralization of drugs and carcinogens and affecting the metabolism of lipids Gut bacteria modulate intestinal motility barrier function and visceral perception A better understanding of the role of microbiota in the proposed GI diseases will have profound impact in the characterization of future biomarkers and has also potential treatment implications As the microbiota may be disturbed in the mentioned GI conditions a possible treatment approach could be to correct dysbiosis either by the administration of an antibiotic or a preparation of beneficial bacteria probiotics according to each bacteria profile
General Objective The objective of this study is to identify different patterns of intestinal microbiota in patients diagnosed with inflammatory bowel disease microscopic colitis functional diarrhea severe motility disorders celiac disease and irritable bowel syndrome and to compare it with non-disease controls by assessing data questionnaires and samples stool blood and tissue from single time point endoscopycolonoscopy appointment
General Objective The objective of this study is to identify different patterns of intestinal microbiota in patients diagnosed with inflammatory bowel disease microscopic colitis functional diarrhea severe motility disorders celiac disease and irritable bowel syndrome and to compare it with non-disease controls by assessing data questionnaires and samples stool blood and tissue from single time point endoscopycolonoscopy appointment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None